



6th Metabolic Syndrome, Type 2 Diabetes
and Atherosclerosis congress

2009



BERLIN

May 20th - 24th 2009

► PROGRAM

Under the aegis of



INTERNATIONAL
ATHEROSCLEROSIS
SOCIETY



International Task Force
for Prevention of
Coronary Heart Disease



Fondation
Cœur et Artères
Recherche et Prévention
Nutrition et Santé



The Scientific Committee and the Organizing Secretariat thank warmly the following actors of the pharmaceutical industry for their support and contribution to the 6th Metabolic Syndrome, type II Diabetes and Atherosclerosis congress.

Diamond sponsor

Solvay
Pharmaceuticals



Gold sponsor



Bayer HealthCare
Bayer Schering Pharma

Silver sponsors



Welcome address

Dear Colleagues,

On behalf of the Organizing Committee, I am very glad to inform you that the 6th edition of the « Metabolic Syndrome, type II Diabetes and Atherosclerosis » congress will be held in Berlin (Germany) from May 20th to May 24th, 2009.

Since its creation, this meeting welcomes a wide number of participants, from all over the world, involved in the atherosclerosis and cardiovascular diseases fields. It covers every item from evolution to definition, from basic research to the latest therapeutic managements and prevention.

Benefiting since its creation from the support of many scientific societies especially the “International Atherosclerosis Society”, the “International Task Force for Prevention of Coronary Heart Disease”, the “Fondation Coeur et Artères”, the “Nouvelle Société Française d’Athérosclérose” and the “Société Française d’Endocrinologie”, the Congress has been designed to provide an innovative and comprehensive overview of the latest research developments in Metabolic Syndrome, Diabetes and Atherosclerosis.

Experts from different fields (cardiologists, diabetologists and scientists) have been invited and will present and discuss a full spectrum of pertinent topics relating to these items in the form of plenary sessions and symposia.

And finally, the Congress will offer the occasion to the participants to present their own papers, so giving the opportunity to share knowledge.

I hope that you will enjoy the congress and that your interaction with your colleagues from many different countries will stimulate a creative exchange of ideas.

Yours sincerely,

Professor Jean-Charles Fruchart
President of International Atherosclerosis Society
Chairman

SCIENTIFIC AND ORGANIZING COMMITTEE


Chair:

Pr Jean-Charles FRUCHART (France)
Atherosclerosis Department
and UR 545 Inserm
Institut Pasteur de Lille
1, rue du Professeur Calmette
59019 Lille Cedex
France
Tel: +33 (0)3 20 87 73 56
Fax: +33 (0)3 20 87 73 19 or 60

Members:

Dr Jamila FRUCHART-NAJIB
Pr Patrick DURIEZ
Pr Bart STAELS

Exhibition map



BOOTH 1: BAYER HEALTHCARE

BOOTH 2: R3I FOUNDATION

BOOTH 3: SOLVAY PHARMACEUTICALS

BOOTH 4: FONDATION CŒUR ET ARTÈRES

C O N T E N T S

Welcome address	3
Scientific and organizing committee	3
Exhibition map	4
Program at a glance	7

DETAILED PROGRAM

Thursday May 21, 2009	
morning	8
afternoon	9
Friday May 22, 2009	
morning	10
afternoon	12
Saturday May 23, 2009	
morning	14
afternoon	15
Sunday May 24, 2009	15

LIST OF POSTER ABSTRACTS	18
Information to the faculty and poster authors	25
General information	26
The congress from A to Z	28



Program at a glance

THURSDAY 21ST MAY	FRIDAY 22ND MAY	SATURDAY 23RD MAY	SUNDAY 24TH MAY
<p>08:45 / 09:00 am</p> <p>CONGRESS OPENING CEREMONY</p>	<p>09:00 / 10:30 am</p> <p>ACADEMIC SESSION 2 Residual risk: macrovascular risk in type II diabetes <i>Chair: Sacks Frank (USA)</i> Sacks Frank (USA) Assmann Gerd (Germany) Fruchart Jean-Charles (France)</p>	<p>09:00 / 10:30 am</p> <p>ACADEMIC SESSION 5 Emerging therapies in metabolic disorders <i>Chair: Davignon Jean (Canada)</i> Ceska Richard (Czech Republic)</p> <p>State of the Art Lecture Athanasiou Thanos (UK)</p>	<p>09:00 / 11:00 am</p> <p>POSTER SESSION <i>Chair: J.-C. Fruchart (France)</i></p>
<p>09:00 / 10:30 am</p> <p>ACADEMIC SESSION 1 Metabolic syndrome and cardiovascular disease <i>Chair: Paoletti Rodolfo (Italy)</i> Hermans Michel (Belgium) Hanefeld Markolf (Germany) Gupta Sandeep (UK)</p>	<p>COFFEE BREAK</p>	<p>COFFEE BREAK</p>	
<p>11:00 / 12:30 pm</p> <p>SYMPOSIUM SPONSORED BY SOLVAY PHARMACEUTICALS Total lipid control, the only approach to optimal vascular risk reduction <i>Chair: Fruchart Jean-Charles (France)</i> Cohen Jerome (USA) Nuñez-Cortes Jesus Millan (Spain) Keech Anthony (Australia) Zambon Alberto (Italy)</p>	<p>11:00 am / 12:30 pm</p> <p>ACADEMIC SESSION 3 Residual risk: microvascular risk in type II diabetes <i>Chair: Fioretto Paola (Italy)</i> Fioretto Paola (Italy) Facsko Andrea (Hungary) Keech Anthony (Australia)</p>	<p>11:00 am / 12:30 pm</p> <p>ACADEMIC SESSION 6 Metabolic syndrome, type II diabetes and vascular inflammation <i>Chair: Calvo Carlos (Chile)</i> Marx Nikolaus (Germany) Koenig Wolfgang (Germany) Staels Bart (France)</p>	
<p>12:30 / 02:00 pm</p> <p>LUNCH</p>	<p>12:30 / 2:00 pm</p> <p>LUNCH SYMPOSIUM SPONSORED BY KOWA Importance of HDL-C <i>Chair: Chapman M. John (France)</i> Schaefer Ernst J. (USA) Yamashita Shizuya (Japan) Farnier Michel (France)</p>	<p>12:30 / 02:00 pm</p> <p>LUNCH</p>	<p>END OF THE CONGRESS</p>
<p>02:00 / 04:00 pm</p> <p>SYMPOSIUM SPONSORED BY BAYER SCHERING PHARMA Towards comprehensive CV risk management <i>Chair: Tendera Michal (Poland)</i> Tendera Michal (Poland) Elliott Henry (UK) Kintscher Ulrich (Germany) Karasik Avraham (Israel) Ikeda Yasuo (Japan) Ruilope Luis (Spain) Tendera Michal (Poland)</p>	<p>02:00 / 03:30 pm</p> <p>ACADEMIC SESSION 4 Post-prandial lipemia and cardiovascular risk <i>Chair: Assmann Gerd (Germany)</i> Rosenson Robert S. (USA) Castro Cabezas Manuel (The Netherlands) Ordovas Jose (USA)</p>	<p>02:00 / 03:30 pm</p> <p>ACADEMIC SESSION 7 New trends in atherosclerosis <i>Chair: Rosenson Robert S. (USA)</i> Farinara Eduardo (Italy) Van Tol Arie (The Netherlands) Duriez Patrick (France) Calvo Carlos (Chile)</p>	
<p>COFFEE BREAK</p>	<p>COFFEE BREAK</p>	<p>COFFEE BREAK</p>	
<p>04:30 / 06:00 pm</p> <p>FONDATION CŒUR ET ARTERES SYMPOSIUM The metabolic syndrome: the crossroads of genes and nutrition <i>Chair: Fruchart Jean-Charles (France)</i> Junien Claudine (France) Froguel Philippe (France) Ziegler Olivier (France)</p>	<p>04:00 / 05:30 pm</p> <p>SYMPOSIUM SPONSORED BY NOVARTIS PHARMA Management of cardiovascular diseases: evolution to new practices ? <i>Chair: Dubois Claude (France)</i> Galinier Michel (France) Vaisse Bernard (France) Huet Dominique (France)</p>	<p>04:00 / 5:00 pm</p> <p>ORAL COMMUNICATIONS SELECTED FROM ABSTRACTS <i>Chair: Duriez Patrick (France)</i></p>	

Thursday May 21, 2009 / Morning

08:45 am
09:00 am

CONGRESS OPENING CEREMONY

09:00 am
10:30 am

ACADEMIC SESSION 1

Metabolic syndrome and cardiovascular disease

Chair: Paoletti Rodolfo (Italy)

- Metabolic syndrome definition:
consensus in progress, an update Hermans Michel (Belgium) **AL-01**
- Metabolic syndrome as cardiovascular risk factor in patients
with prediabetes and clinical type 2 diabetes Hanefeld Markolf (Germany) **AL-02**
- Ethnicity - as a CV risk factor ? Gupta Sandeep (UK) **AL-03**

10:30 am
11:00 am

Coffee Break

11:00 am
12:30 pm

SYMPOSIUM SPONSORED BY SOLVAY PHARMACEUTICALS

Total lipid control, the only approach to optimal vascular risk reduction

Chair: Fruchart Jean-Charles (France)

- TG, the forgotten variable in the vascular risk equation: Paying the price
of skyrocketing TG levels - NHANES data Cohen Jerome (USA) **LL-01**
- Investigating atherogenic dyslipidemia
and the residual vascular risk Nuñez-Cortes Jesus Millan (Spain) **LL-02**
- FIELD: macro and micro-vascular results Keech Anthony (Australia) **LL-03**
- Evolution of the lipid guidelines, statins are not enough anymore ! Zambon Alberto (Italy) **LL-04**

Thursday May 21, 2009 / Afternoon

12:30 pm
02:00 pm

Lunch

02:00 pm
04:00 pm

SYMPOSIUM SPONSORED BY BAYER SCHERING PHARMA

Towards comprehensive CV risk management

Chair: Tendera Michal (Poland)

- Introduction: how to address the increasing global CV risk Tendera Michal (Poland) **LL-05**
- The need for effective BP lowering...to target Elliott Henry (UK) **LL-06**
- ARBs and the metabolic syndrome Kintscher Ulrich (Germany) **LL-07**
- Safe diabetes therapy providing CV benefits Karasik Avraham (Israel) **LL-08**
- Event prevention across the CV risk continuum Ikeda Yasuo (Japan) **LL-09**
- Comprehensive CV risk management - what does it mean ? Ruilope Luis (Spain) **LL-10**
- Closing remarks Tendera Michal (Poland) **LL-11**

04:00 pm
04:30 pm

Coffee Break

04:30 pm
06:00 pm

FONDATION CŒUR ET ARTÈRES SYMPOSIUM

The metabolic syndrome: the crossroads of genes and nutrition

Chair: Fruchart Jean-Charles (France)

- Epigenetic of the metabolic syndrome Junien Claudine (France) **LL-12**
- Genetic of the metabolic syndrome Froguel Philippe (France) **LL-13**
- Is diet guilty of the metabolic syndrome progression? Ziegler Olivier (France) **LL-14**

Friday May 22, 2009 / Morning

09:00 am
10:30 am

ACADEMIC SESSION 2

Residual risk: macrovascular risk in type II diabetes

Chair: Sacks Frank (USA)

- Atherogenic dyslipidemia: components and actors in CVD Sacks Frank (USA) **AL-04**
- Non-LDL - Related dyslipidemia and coronary risk Assmann Gerd (Germany) **AL-05**
- Macrovascular residual risk reduction in patients
with type II diabetes Fruchart Jean-Charles (France) **AL-06**

10:30 am
11:00 am

Coffee Break

11:00 am
12:30 pm

ACADEMIC SESSION 3

Residual risk: microvascular risk in type II diabetes

Chair: Fioretto Paola (Italy)

- Residual risk of microvascular complications of diabetes:
focus on nephropathy Fioretto Paola (Italy) **AL-07**
- Residual risk of microvascular complications of diabetes:
focus on retinopathy Facsko Andrea (Hungary) **AL-08**
- Macrovascular and microvascular residual risk reduction: current limitations
and insights into the future Keech Anthony (Australia) **AL-09**



MSDA

**7th Metabolic Syndrome, type II Diabetes
and Atherosclerosis congress**

2010

MARRAKESH
MAY 12th - 16th
2010

ORGANIZING / SCIENTIFIC COMMITTEE

Chair: Pr Jean-Charles FRUCHART

ORGANIZING SECRETARIAT

PLB. Organisation Inc. / MSDA 2010

Phone: (+33) (0)1 39 04 24 24 - Fax: (+33) (0)1 39 04 07 41 - Email: msda2010@agence-plb.com

Web site: www.msdacongress.com

Friday May 22, 2009 / Afternoon

12:30 pm
02:00 pm

LUNCH SYMPOSIUM SPONSORED BY KOWA

Importance of HDL-C

Chair: Chapman M. John (France)

- HDL particles, metabolism and cardiovascular disease Schaefer Ernst J. (USA) **LL-15**
- Mechanisms and clinical significance of HDL - C elevation by statins
..... Yamashita Shizuya (Japan) **LL-16**
- Clinical impact on cardiovascular risk of low HDL - C Farnier Michel (France) **LL-17**

02:00 pm
03:30 pm

ACADEMIC SESSION 4

Post-prandial lipemia and cardiovascular risk

Chair: Assmann Gerd (Germany)

- Fasting or postprandial triglyceridemia:
review of the evidence and future directions Rosenson Robert S. (USA) **AL-10**
- Mechanisms of postprandial inflammation in relation to atherosclerosis:
triglycerides or glucose ? Castro Cabezas Manuel (The Netherlands) **AL-11**
- The genetic architecture of fasting plasma triglyceride
response to fenofibrate treatment Ordovas Jose (USA) **AL-12**

03:30 pm
04:00 pm

Coffee Break

04:00 pm
05:30 pm

SYMPOSIUM SPONSORED BY NOVARTIS PHARMA

Management of cardiovascular diseases: evolution of new practices ?

Chair: Dubois Claude (France)

- From hypertension to heart failure :The interest of ARBs Galinier Michel (France) **LL-18**
- Renin-angiotensin system: new therapeutic approaches ? Vaisse Bernard (France) **LL-19**
- News regarding the management of type II diabetes Huet Dominique (France) **LL-20**



Kowa

Kowa Company, Ltd.

4-14, Nihonbashi-Honcho 3-Chome, Chuo-ku, Tokyo, Japan
For more information see : www.kowa.co.jp

Saturday May 23, 2009 / Morning

9:00 am
10:30am

ACADEMIC SESSION 5

Emerging therapies in metabolic disorders

Chair: Davignon Jean (Canada)

- PCSK9: a place in clinical practice now or later? Davignon Jean (Canada) **AL-13**
- The lower, earlier and longer - The better in the treatment of DLP
..... Ceska Richard (Czech Republic) **AL-14**

State of the Art Lecture

Athanasiou Thanos (UK)

- An overview of the current metabolic surgical operations and their benefits and risks **AL-15**

10:30 am
11:00 am

Coffee Break

11:00 am
12:30 pm

ACADEMIC SESSION 6

Metabolic syndrome, type II diabetes and vascular inflammation

Chair: Calvo Carlos (Chile)

- Lymphocytes in adipose tissue inflammation and vascular disease..Marx Nikolaus (Germany) **AL-16**
- Oxidative stress and atherosclerosis in patients with impaired glucose metabolism:
is there a potential role for Lp-PLA2 inhibition?Koenig Wolfgang (Germany) **AL-17**
- Bile acids: from simple detergents to complex signalling molecules
controlling lipid and glucose homeostasisStaels Bart (France) **AL-18**

Saturday May 23, 2009 / Afternoon

12:30 pm
2:00 pm

Lunch

2:00 pm
3:30 pm

ACADEMIC SESSION 7

New trends in atherosclerosis

Chair: Rosenson Robert S. (USA)

- An overview on alcohol consumption, protective effect and cardiovascular riskFarinaro Eduardo (Italy) **AL-19**
- Mechanisms causing atherosclerosis in transgenic mice with elevated plasma PLTP activityVan Tol Arie (The Netherlands) **AL-20**
- Is CETP really a hopelessly bad drug target ?Duriez Patrick (France) **AL-21**
- Relation of Lp-PLA2 and CETP activities with endothelial dysfunction Calvo Carlos (Chile) **AL-22**

3:30 pm
4:00 pm

Coffee Break

4:00 pm
5:00 pm

ORAL COMMUNICATIONS SELECTED FROM ABSTRACTS

Chair: Duriez Patrick (France)

- Conference 1
Reversal of inflammation-induced impairment of glucose uptake in adipocytes by direct effect of CB1 antagonism on adipose tissue macrophages.....Miranville Alexandra (Germany) **P-18**
- Conference 2
What's the relation between inflammatory markers and intimal media thickness in diabetics with negative myocardial perfusion scan ?Shakir Douraid K.(Qatar) **P-01**
- Conference 3
The -1131T>C SNP of the APOA5 gene modulates response to Fenofibrate treatment in patients with the metabolic syndrome: a post-prandial studyCardona Fernando (Spain) **P-35**
- Conference 4
Insulin Resistance in Non-Diabetic Saudi Adults is better detected by the Incorporation of Fasting Free Fatty Acids into QUICK I than by HOMA or QUICK IAkbar Daad (Saudi) **P-08**

Sunday May 24, 2009

9:00 am
11:00 am

POSTER SESSION

Chair: Fruchart Jean-Charles (France)

List of poster abstracts

P01 What's the relation between inflammatory markers and media thickness in diabetics with negative myocardial perfusion scan?

Douraid K. Shakir, I Mohammed, M Zarie, D Al Kateeb, A S Kiliyanni, J Al Suwaidi

Hamad Medical Corporation, Doha, Qatar -dshakir@hotmail.com, Tel: 009745239848, Fax: 00 974 4134855

P02 Gender specific variations in the intensity and location of Angina Pectoris

Tahereh Najafi Ghezjeljeh,

BScN, RN, MScN, Lecturer, Nursing and Midwifery faculty, Iran University of Medical Sciences, Tehran, Iran; PhD Candidate at Karolinska Institutet, Stockholm, Sweden

Mahmoud Momtahan,

MD, Associate Professor of Cardiology, Tehran, Iran

Mesfin Kassaye Tessma

MD, MPH, Medical Statistics Unit, Karolinska Institutet, Stockholm, Sweden.

Mansoureh Yadavar Nikravesht

PhD, Associate Professor, Nursing and Midwifery faculty, Iran University of Medical Sciences

Inger Ekman RN,

PhD, Professor, the Sahlgrenska Academy at Gothenburg University, Sweden

Azita Emami RN,

RNT, PhD, Professor, Dean of College of Nursing, Seattle University

P03 Aporphine Alkaloid, Boldine Modulates Adiponectin Levels in 3T3-L1 Cells

*N. Santanam PhD, *B. Yu, PhD, C. Cook BS, J. Fei PhD*

Joan C. Edwards School of Medicine, Huntington, WV and *LSUHSC, N. Orleans, LA, USA

P04 Gender Differences in Epicardial Fat Adipokines in Aging Fisher 344 x Brown Norway Hybrid Rats

N. Santanam, PhD, F. Jia, PhD, E. Blough, PhD

Joan C. Edwards School of Medicine, Huntington, WV, USA

P05 Stress hyperglycemia and acute myocardial infarction

Mehmooosh Boroomandpoor, MD, Mohsen Rahimi, MD. Mohammad Reza Rajabi, MD. Simindokht Moshar, MD. Motahhare Rajabi, MD.*

Booali heart center, Azad University, Tehran, Iran.

P06 Association between Troponin I level and left ventricular function of less than 40% in patients in first attack of acute myocardial infarction

Mehmooosh Boroomandpoor, MD, Mohsen Rahimi, MD. Reza Mohammadi, MD. Neda Ghaem Meghami MD*

Booali heart center, Azad University, Tehran, Iran.

P07 Metabolic Syndrome and the risk of cardiovascular disease among Cuban men and women

Valdés López, Y. MD,

Clinical Laboratory resident, Department of Biochemistry, "Victoria de Girón" Basic and Preclinical Sciences Institute, Havana, Cuba.

Suárez Bergada, R. MD,

Clinical practitioner, Department of Internal Medicine, "Hermanos Ameijeiras" Hospital, Havana, Cuba.

P08 Insulin Resistance in Non- Diabetic Saudi Adults is better detected by the Incorporation of Fasting Free Fatty Acids into QUICK I than by HOMA or QUICK I

D Akbar⁽¹⁾, S Bahjiri⁽²⁾, E Al issa⁽³⁾ and T Ghabra⁽⁴⁾

(1) Professor of Internal Medicine, (2) professor of Biochemistry, (3) Assistant Professor of Biochemistry, (4) Associate Professor Community Medicine, all authors from King Abdulaziz University, Jeddah, Saudi Arabia. E.mail: daadakb@gmail.com

P09 Prolonged treatment with N-acetylcysteine and L-arginine restores gonadal function in patients with PCO syndrome

V. Martina, A. Masha, C. Manieri, S. Dinatale, G.A. Bruno, E. Ghigo.

Department of Internal Medicine, Division of Endocrinology, University of Turin, Italy

P10 Protein alterations in LDL and HDL from obese subjects; increased levels of transthyretin

*Helen Karlsson MD¹, Harriet Mörtstedt PhD², Helen Lindqvist MD³, Christer Tagesson Prof.¹,
Mats Lindahl Ass. Prof.¹*

(1) Division of Occupational and Environmental Medicine, Department of Clinical and Experimental Medicine, Linköping University, Sweden, (2) Department of Occupational and Environmental Medicine, Lund University Hospital, Sweden (3) Department of Chemistry and Bioscience/Food Science, Chalmers University of Technology, Göteborg, Sweden

P11 Human carotid atherosclerotic lesion promotes oxidation whereas PON1 attenuate such oxidation

Jacob Vaya†, Hagai Tavori‡, ‡ Soliman Khatib†, Michael Aviram‡,*

† Laboratory of Natural Medicinal Compounds, MIGAL – Galilee Technology Center, P.O. Box 831, Kiryat Shmona 11016, and Tel Hai College, Israel., ‡ Rappaport Family Institute for Research in the Medical Science, Rambam Medical Center, Haifa 31096, Israel

P12 FATTY ACID BINDING PROTEIN 4 AS A RISK FACTOR FOR ATHEROSCLEROSIS

Anna Meiliana¹, Chandra Ninghayu¹, Yani Lina¹, Ilhamjaya Patellongi², Gatot SL2, Andi Wijaya².

(1) Prodia Clinical Laboratory, Indonesia (2) Medicine Department, University of Hassanuddin, Makassar, Indonesia

P13 Protective Effect of KMUP-1 against ET-1-Induced Cardiac Hypertrophy in H9c2 Cells

S.F.Liou PhD^a, Y.T.Chen BS^b, L.Y.Chen BS^b, I.J.Chen PhD^b, J.L.Yeh PhD^b

(a) Department of Pharmacy, Chia-Nan University of Pharmacy and Science, Tainan, Taiwan (b) Department and Graduate Institute of Pharmacology, College of Medicine, Kaohsiung Medical University, Taiwan

P14 Lowering high glucose-induced adhesion molecules by lipophilic extract of Chlorella in SEVC cells

M-F, Shih, Y-T HSI*

Department of Pharmacy, Chia-Nan University of Pharmacy & Science, Taiwan

P15 Effect of Atorvastatin on Oxidative Stress Parameters and Lipid Profile in Type 2 Diabetic Patients

Dr. Najah R. Hadi, Kufa College of Medicine, Dr. Bassim I Mohammad, Diwaniya College of Medicine, Dr. Mohammad A Abdelhussein, Kufa College of Medicine

P16 Effects of Carvedilol Add-on Treatment on Insulin Resistance and Blood Pressure in Hypertensive Patients with Type 2 Diabetic Nephropathy

G. Yasuda MD, D. Ando MD, M. Kobayashi MD, K. Yatsu MD, N. Hirawa MD, S. Umemura MD

Division of Nephrology, Center Hospital, Yokohama City University – Kanagawa – Japan

P17 GENE-NUTRIENT INTERACTIONS OF TCF7L2 RS7903146 VARIANT AFFECT BLOOD GLUCOSE LEVELS IN THE GENDAI COHORT.

*George VZ Dedoussis¹, Konstantinos S. Sfaelos¹, Mary Yannakoulia¹, Constantina Papoutsakis¹, Johannah Butler³, Joel N. Hirschhorn^{2,5},
Helen N. Lyon^{2,3,6}*

(1) Department of Dietetics – Nutrition, Harokopio University, Athens, Greece (2) Program in Medical and Population Genetics and Metabolism Initiative, Broad Institute of Harvard and MIT, Cambridge, Massachusetts (3) Division of Genetics, Program in Genomics, Children's Hospital, Boston, Massachusetts (4) Division of Endocrinology, Children's Hospital, Boston, Massachusetts (5) Department of Genetics, Harvard Medical School, Boston, Massachusetts (6) Department of Paediatrics, Harvard Medical School, Boston, Massachusetts

P18 Reversal of inflammation-induced impairment of glucose uptake in adipocytes by direct effect of CB1 antagonism on adipose tissue macrophages

Miranville A., Herling A.W., Biemer-Daub G., Voss MD.

Sanofi-Aventis Deutschland GmbH, Therapeutic Department Metabolism, Frankfurt/Main, Germany

P19 THE CORRELATION OF SERUM APELIN LEVELS WITH INSULIN RESISTANCE, COMMON CAROTIS ARTERY PULSATILITY AND RESISTIVITY INDEX IN TYPE 2 DIABETIC SUBJECTS

C.Top MD, G. Ozdemir MD, F.Tangi MD, B. Sahan MD, C.Oktenli MD

Department of Internal Medicine, Gülhane Military Medical Academy, Haydarpasa Training Hospital, Istanbul, Turkey

List of poster abstracts

P20 Inhibitors and breakers of AGEs : An M.O comparative study of mechanisms of action of Metformin, Aminoguanidine and Pyridoxamine

B. Maouche¹ Pr., D. Ikhlef² Dr and S. El-Aoufi² M.C.

(1) Laboratoire de Physicochimie Théorique et Chimie Informatique, Faculté de Chimie, USTHB, Alger – Algérie (2) Laboratoire de Biologie et de Physiologie des Organismes/Nutrition, Métabolisme, Faculté des Sciences Biologiques, USTHB, Alger – Algérie.

P21 The effect of a high calorie diet on the pathologies of the hepatic tissue in sand rat (*Psammomys obesus*): histochemical and histoenzymologic study

S. El-Aoufi¹ M.C, B. Maouche² Pr., S. Sennoune³ Dr and L. Griene⁴ Pr.

(1) Laboratoire de Biologie et de Physiologie des Organismes/Nutrition, Métabolisme, Faculté des Sciences Biologiques, USTHB, Alger – Algérie. (2) Laboratoire de Physicochimie Théorique et de Chimie Informatique ; Faculté de Chimie, USTHB, Alger, Algérie. (3) Department of Physiology; Texas Tech University Health Sciences Center ; Lubbock, Texas – USA. (4) Laboratoire d'Hormonologie, Centre Pierre et Marie Curie, C.H.U Mustapha, Alger – Algérie

P22 Hypercholesterolaemia and statin treatment among middle-aged patients admitted to the East-Tallinn Central Hospital (Estonia) for emergency PTCA

E. Mäeots, MD, K. Traumann, RN BA Sc, K. Tutt, RN BA

East – Tallinn Central Hospital – Tallinn – Estonia

P23 Distribution of Adiponectin in Patients with Coronary Artery Disease and its Association with Systemic Inflammation, Obesity and Diabetes Type 2

A.V. Rodina¹ • E.M. Paltseva¹ • D.A. Andreev¹ • E.G. Ponomar¹ • D.E. Gusev¹ • S.E. Severin² • A.L. Syrkin¹.

(1) Clinical Center I.M. Sechenov Moscow Medical Academy – Moscow – Russia (2) Research Institute of Molecular Medicine I.M. Sechenov MMA- Moscow – Russia

P24 Effect of Adjunct Metformin Treatment on Levels of Plasma Lipids in Patients with Type-1 Diabetes.

S. S. Lund MD¹, L. Tarnow MD, DMSc¹, A. S. Astrup MD¹, P. Hovind MD, DMSc¹, P.K. Jacobsen MD, DMSc¹, A. C. Alibegovic MD¹, I. Parving¹, L. Pietraszek¹, M. Frandsen¹, P. Rossing MD, DMSc¹, H.-H. Parving MD, DMSc, Prof² and A. A. Vaag MD, PhD, DMSc, Prof¹.

(1) Steno Diabetes Center, Gentofte, Denmark. (2) Rigshospitalet, Copenhagen, Denmark.

P25 MODULATION OF MONOCYTE CD36 BY ATHEROSCLEROTIC RISK FACTORS

Bernal-Lopez MR^{ad}, Llorente-Cortes V^b, Mayas MD^a, López-Carmona D^c, Gomez-Huelgas R^c, Tinahones FJ^{ad}, Badimon L^{bd}.

(a) Research Laboratory. Endocrinology Department. Hospital Virgen de la Victoria. Málaga. (b) Cardiovascular Research Center, CSIC-ICCC, Hospital de la Santa Creu i Sant Pau, Barcelona. (c) Internal Medicine Department, Hospital Carlos Haya, Málaga. (d) CiberObn (CB06/003). SPAIN.

P26 PREVALENCE OF THE METABOLIC SYNDROME AND THE CLASSICAL CARDIOVASCULAR RISK FACTORS IN MALAGA (SPAIN). (IMAP STUDY. MULTIDISCIPLINARY INTERVENTION IN PRIMARY ATTENTION)

Gómez-Huelgas R¹, Mancera-Romero², Jansen-Chaparro S¹, Baca-Osorio AP, Guijarro-Merino R¹, López-Carmona MD¹, Bernal-López MR³, Tinahones F¹.

(1) Internal Medicine Department. Hospital Carlos Haya. Málaga. (2) Health Centre “Ciudad Jardín”. Málaga. (3) Endocrinology Department. Hospital Virgen de la Victoria. Málaga. SPAIN.

P27 Anti-diabetic effects and mechanism of *Bidens pilosa* water extract

Wen-Chin Yang . Yi-Jou Hsu . Tsung-Han Lee . Cicero Lee-Tian Chang

Agricultural Biotechnology Research Center, Academia Sinica, Taiwan, R.O.C. Department of Life Sciences, National Chung Hsing University, Taiwan, R.O.C. Department of Veterinary Medicine, National Chung Hsing University, Taiwan, R.O.C.

P28 The development of metabolic menopausal syndrome in exertional angina menopausal women

I.Karpova, O.Barbuk, S.Matskevich, S.Solovey

The Scientific and Practical Center of Cardiology, Minsk (Belarus)

P30 Transgenic expression of human C-reactive protein induces oxidative stress in the spontaneously hypertensive rats

O. Oliyarnyk¹, H. Malinska¹, M. Maxova¹, M. Hubova¹, L. Kazdova¹, V.Landa¹, M. Pravenec²;

(1) Department of Metabolism and Diabetes, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, (2) Institute of Physiology, Academy of Sciences, Prague, Czech Republic.

P31 Evaluation of Obesity in Relation to the Metabolic Syndrome (Atp Iii-Criteria) and the Classical Cardiovascular Risk Factors in Patients with Acute Myocardial Infarction.

Kyriazis I.¹, Mellos C.², Chatzidaki P.¹, Mytas D.³, Bader M.³, Dilanas C.³, Papas L.³, Theodoropoulou P.², Mendrinou D.², Lalousis A.¹, Deda E.¹, Mallios I.², Dimitriou P.², Kostogianopoulou P.², Koutouzi S.², Kokolias T.², Giolis A.², Partheniou Ch.¹, Pyrgakis V.³

(1) Diabetes Outpatient Clinic Korinthos General Hospital, (2) Internal Medicine Dpt., Korinthos General Hospital, (3) Cardiology Dpt., Korinthos General Hospital, Korinthos, Greece.

P32 The Presence and Modulation Grade of Dyslipidemia as well as the Influence of Hypolipidemic Treatment with Statins among Patients with First-Onset Acute Myocardial Infarction and their In-hospital Prognosis

Kyriazis I.¹, Mellos C.¹, Chatzidaki P.¹, Mytas D.³, Bader M.³, Dilanas C.³, Papas L.³, Theodoropoulou P.², Mendrinou D.², Lalousis A.¹, Deda E.¹, Mallios I.², Dimitriou P.², Kostogianopoulou P.², Koutouzi S.², Kokolias T.², Giolis A.², Partheniou Ch.¹, Pyrgakis V.³

(1) Diabetes Outpatient Clinic Korinthos General Hospital, (2) Internal Medicine Dpt., Korinthos General Hospital, (3) Cardiology Dpt., Korinthos General Hospital, Korinthos, Greece.

P33 The role of lipoprotein lipase activity, hyperinsulinemia and free fatty acids in genesis of combined hyperlipoproteinemia and hypertriglyceridemia.

Elena V Ageeva, Ylia V Frolova PhD, Korney V Bondar, Alexander D Denisenko MD PhD.

Russian Academy of Medical Sciences, Department of Biochemistry, Institute of Experimental Medicine, Saint-Petersburg, Russia.

P34 OXIDATIVE STRESS AFTER FAT OVERLOAD IN PERSONS WITH BASELINE HYPERTRIGLYCERIDEMIA WITH OR WITHOUT THE METABOLIC SYNDROME

F Cardona¹, M¹ Murri, M² Queipo-Ortuño, FJ¹ Tinahones

(1) CIBER Fisiopatología Obesidad y Nutrición (CB06/03) Instituto de Salud Carlos III, Servicio de Endocrinología y Nutrición, Hospital Clínico Universitario Virgen de la Victoria, 29009 Malaga Spain. (2) Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad de Málaga, 29010 Málaga, Spain.

P35 THE -1131T>C SNP OF THE APOA5 GENE MODULATES RESPONSE TO FENOFIBRATE TREATMENT IN PATIENTS WITH THE METABOLIC SYNDROME: A POST-PRANDIAL STUDY

Fernando Cardona¹, Montserrat Guardiola², María Isabel Queipo-Ortuño^{1,3}, Mora Murri¹, Josep Ribalta², Francisco J Tinahones¹

(1) Servicio de Endocrinología y Nutrición. Hospital Virgen de la Victoria, Málaga, Spain. CIBER Fisiopatología de la Obesidad y Nutrición (06/03). (2) Unitat de Recerca en Lípids i Arteriosclerosi, Universitat Rovira i Virgili, Reus, Spain. (3) Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad de Málaga.

P36 Prevalence of Metabolic Syndrome Components and Their Associations with Biomedical Characteristics in Elderly Russian Population

V. Metelskaya¹ PhD, M. Shkolnikova² MD, S. Shalnova¹ MD, E. Andreev² PhD, A. Deev¹ PhD, N. Perova¹ MD, V. Shkolnikov² PhD

(1) National Research Center for Preventive Medicine, Moscow, Russia (2) Max-Planck Institute for Demography Research, Rostock –Germany

P37 MRI of Endothelial Adhesion Molecules in Carotid Atherosclerosis Using Targeted Ultra-small Superparamagnetic Particles of Iron Oxide (USPIO) – Towards an In Vivo Model

J. Chan¹, K. Bhakoo², C. Monaco³, R. Gibbs¹

(1) Vascular surgery unit, St Mary's Hospital, Imperial College, London, U.K. (2) Stem Cell Imaging Group, Imperial College, London, U.K. (3) Kennedy Institute of Rheumatology, Imperial College, London, U.K.

P38 Lp-PLA2 and computation mathematic agent-based model factor analysis in patients with dyslipoproteinemia

J. Turay, MD, J. Vd'ľka, PhD, V. Grniaková, dipl. Ing.

Metabolic Unit, Metabolic Centrum, Zvolen, Slovakia, Slovak Academy of Sciences, Institute of Ecology, Dept. Biomathematics, Zvolen, Slovakia

List of poster abstracts

P39 Long-term pioglitazone treatment increases PKC ϵ and PKC θ activity in skeletal muscles in experimental model of insulin resistance

I. Markova¹ • L. Kazdova¹ • M. Pravenec¹

(1) Institute for Clinical and Experimental Medicine – Prague - Czech Republic (2) Institute of Physiology - Czech Academy of Sciences - Prague - Czech Republic

P40 Metabolic effects of conjugated linoleic acid in an experimental model of metabolic syndrome

H. Malínská • M. Maxová • M. Hubová • L. Kazdová

Institute for Clinical and Experimental Medicine – Prague – Czech Republic

P41 The effect of transgenic expression of human C-reactive protein on insulin resistance and adipocytokines levels in the spontaneously hypertensive rats

M. Maxová¹ • L. Kazdová¹ • M. Pravenec¹

(1) Institute for Clinical and Experimental Medicine, Prague, Czech Republic (2) Institute of Physiology, Academy of Sciences, Prague, Czech Republic

P42 High density lipoprotein- cholesterol distribution and prevalence of low HDL-c levels in Lleida (Spain)

Caldero M, Pena M, Sanchez V, Quesada A, Mollo A, Llovet R, Villanueva M, Llarden M, Falguera M, Rodríguez A., Baillo P.

ABS Pla d'Urgell. Centre d'Atenció Primària Mollerussa. Lleida. Spain

P43 Relationship between High Density Lipoprotein-Cholesterol and insulin resistance markers

Caldero M, Quesada A, Sanchez V, Pena M, Llovet R, Mollo A, Llarden M, Falguera M, Rodríguez A, Real J, Sarriegui S.

ABS Pla d'Urgell. Centre d'Atenció Primària Mollerussa. Lleida. Spain

P44 Is good cholesterol linked to kidney function?

Caldero M, Pena M, Sanchez V, Quesada A, Mollo A, Marsal JR, Llovet R, Llarden M, Falguera M, Rodríguez A.

ABS Pla d'Urgell. Centre d'Atenció Primària Mollerussa. Lleida. Spain

P45 WAIST CIRCUMFERENCE AND ITS ASSOCIATION WITH TYPE 2 DIABETES IN LLEIDA (SPAIN)

CALDERO M, QUESADA A, PENA M, SANCHEZ V, LLOVET R, VILLALBA L, MOLLO MA, FALGUERA M, RODRIGUEZ A, PERELLO I, SANGRA J.

ABS Pla d'Urgell. Centre d'Atenció Primària Mollerussa. Lleida. Spain

P46 Epidemiology of metabolic syndrome in Lleida (Spain)

Caldero M, Sanchez V, Quesada A, Pena M, Falguera M, Rodriguez A, Pascual G, Mollo A, Lafarga A, Marsal JR.

ABS Pla d'Urgell. Centre d'Atenció Primària Mollerussa. Lleida. Spain

P47 Epidemiology of obesity in Lleida (Spain)

Caldero M, Sanchez V, Pena M, Quesada A, Rodriguez , Falguera M, Pascual G, Mollo A, Ciria C, Albalad JM.

ABS Pla d'Urgell. Centre d'Atenció Primària Mollerussa. Lleida. Spain

P48 Metabolic syndrome among post-menopausal women in Lleida

Caldero M, Llovet R, Sanchez V, Pena M, Molló MA, Quesada A, Falguera M, Rodriguez A, Chacón M, Llardén M.

ABS Pla d'Urgell. Centre d'Atenció Primària Mollerussa. Lleida. Spain

P49 Self-perception of weight on metabolic syndrome. Are we aware of our weight effect?

Caldero M, Llovet R, Pena M, Sanchez V, Mollo MA, Quesada A, Rodriguez A, Falguera M, Sanz E., Miquel E.

ABS Pla d'Urgell. Centre d'Atenció Primària Mollerussa. Lleida. Spain

P50 Workplace-medicine, an opportunity to treat the metabolic syndrome: the experience of the "FAO Medical Service Coronary Heart Disease Prevention Programme"

R. Volpe, J. Pille, R. Gavita, A. Rossetti, S. Valle³

Italian National Council Research (CNR), Rome, Italy; (1) Food and Agriculture Organization (FAO) of the United Nations, Rome, Italy;

(2) Cardiology Unit, Villa Betania-Santo Spirito Hospital, Rome, Italy; (3) Laziosanità-Agenzia di Sanità Pubblica della Regione Lazio, Italy.

- P51 A High Expression of Liver Fructokinase is Involved in the Production of Insulin Resistance in Female Rats Ingesting Liquid Fructose**
N. Roglans PhD, L. Vilà PhD, M. Alegret PhD, J.C. Laguna PhD
Pharmacology Section, Department of Pharmacology and Therapeutic Chemistry, School of Pharmacy, Universitat de Barcelona. Members of IBUB and CIBERDEM, Spain
- P52 Inflammation and atherosclerosis: potential role for interleukin-1 receptors**
M. Alegret, J. Pou, A. Rebollo, J.C. Laguna
Pharmacology Department, Faculty of Pharmacy and Biomedicine Institute (IBUB), University of Barcelona and Ciber Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM), Instituto de Salud Carlos III, Spain.
- P53 Fructose effects on Fa0 hepatoma cells**
A. Rebollo, M. Alegret, J. Chavez, N. Roglans, J.C. Laguna
Pharmacology Department, Faculty of Pharmacy and Biomedicine Institute (IBUB), University of Barcelona and Ciber Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM), Instituto de Salud Carlos III, Spain.
- P54 Prevalence of haemoglobin variants in the Tunisian diabetic population**
K.Bouzid, A.Bartkiz, Y.Hamdane, L.Zerelli, A.Bahlous, J.Abdelmoula.
Biochemistry Department- Charles Nicolle Hospital; Tunis-Tunisia.
- P55 Nephropathy in Patients with Coronary Disease and Type 2 Diabetes Mellitus**
**B. Sreckovic, V.Dimitrijevic-Sreckovic, P.Djordjevic, **E. Colak, I. Soldatovic, **V. Barac, B.Zvizdic*
Institute of Endocrinology, Diabetes and Metabolic Diseases, Clinical Center of Serbia, *Clinical Center Bezanijska Kosa, **Institute of Medical Biochemistry, Clinical Center of Serbia; Belgrade, Serbia.
- P56 Increased Insulin Resistance, Reduced Antioxidant Status and Prediabetes in Adolescents with Pre-Metabolic and Metabolic Syndromes**
*V Dimitrijevic-Sreckovic, *B Sreckovic, **E Colak, P.Djordjevic, S. Damjanovic, M.Civcic, I Soldatovic, M Cvetkovic, A Stamenkovic*
Institute of Endocrinology, Diabetes and Metabolic Diseases, *Clinical Center Bezanijska Kosa, **Institute of Medical Biochemistry, Clinical Center of Serbia; Belgrade, Serbia.
- P58 Effect of overweight and high blood pressure on plasma lipid levels in schoolchildren from Serbia**
S. Spasic, D. Dzelajlija, N. Bogavac-Stanojevic and J. Kotur-Stevuljevic
Department of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade – Belgrade - Serbia
- P59 Factor analysis of risk variables associated with iron status in patients with coronary artery disease**
V.Spasojevic-Kalimanovska¹, N. Bogavac-Stanojevic¹, S. Spasic¹, Z.Jelic-Ivanovic¹, J. Kotur-Stevuljevic¹, D.Kalimanovska-Ostrijc²
(1) Institute of Medical Biochemistry, Faculty of Pharmacy, Belgrade, Serbia (2) Institute for Cardiovascular Diseases, Clinical Centre of Serbia, Belgrade, Serbia
- P60 Evaluating Benchmarking to Optimize Management of Type 2 Diabetic Patients: The Belgian Data**
M. P. Hermans¹, E. Muls², F. Nobels³, G. Krzentowski⁴, N. Claes⁵, N. Debacker⁶, A. Matthys⁷.
(1) UCL St-LUC, Brussels, Belgium (2) UZ Gasthuisberg, Leuven, Belgium (3) OLV Ziekenhuis, Aalst, Belgium (4) CHU Charleroi, Charleroi, Belgium (5) Universiteit Hasselt, Diepenbeek, Belgium (6) Wetenschappelijk Instituut Volksgezondheid, Brussels, Belgium (7) AstraZeneca, Brussels, Belgium
- P61 Modulating the Lipid metabolism in Perirenal White Adipose Tissues by Ingestion of "Benifuuki" Green Tea Leaves - Insights into the Down-regulation of Fatty Acid Synthesis-Related Gene Expression**
H. Inagaki PhD, E. Nishimura PhD, Y. Oritani, M. Sugitani, I. Kurita, Y. Setoguchi, K. Abe PhD, T. Ito PhD*
Health Care Division MORINAGA & Co., Ltd.- Yokohama – JAPAN
* Graduate School of Agricultural and Life Sciences – The University of Tokyo –Tokyo - JAPAN
- P62 Comparative Efficacy of Combined Therapy in Patients with Stable Angina Pectoris in Metabolic Syndrome**
Petelina T.I., Musihina N.A., Gapon L.I., Bahmatova Yu.A.
Tyumen Cardiology Center, Tyumen, Russia

List of poster abstracts

P63 Comparative Assessment of Eprosartan and Enalapril in Patients with Essential Hypertension Accompanied by Abdominal Obesity

Petelina T.I., Gapon L.I., Musihina N.A., Kalinina V.A., Avdeeva K.S.
Tyumen Cardiology Center, Tyumen, Russia

P64 Reference intervals for glycated haemoglobin in healthy Tunisian adults

K.Bouزيد¹, Y.Hamdane¹, A.Chelbi¹, L.Zerelli¹, A. Ben Hamida², A.Bahlous¹, J.Abdelmoula¹.
(1) Biochemistry Department- Charles Nicolle Hospital;Tunis-Tunisia. (2) Preventive and Social Medicine Department- University of Medicine;Tunis-Tunisia

P65 Correlation of glycated haemoglobin with fasting blood glucose in Tunisian diabetic patients

K.Bouزيد¹, Y.Hamdane¹, A.Bartkiz¹, L.Zerelli¹, A. Ben Hamida², A.Bahlous¹, J.Abdelmoula¹.
(1) Biochemistry Department- Charles Nicolle Hospital;Tunis-Tunisia. (2) Preventive and Social Medicine Department- University of Medicine;Tunis-Tunisia

P66 Does folic acid correct the hyperhomocysteinemia induced by the fenofibrate?

A.Bahlous¹, K.Bouزيد¹, N.Farjallah¹, H.Abid², L.Zerelli¹, N. Khalfallah², J.Abdelmoula¹.
(1) Biochemistry Department- Charles Nicolle Hospital;Tunis-Tunisia. (2) Department of internal Medicine 10/4- Charles Nicolle Hospital; Tunis-Tunisia.

P67 Eccentric Endurance Exercise Significantly Improves Fasting Glucose and Glucose Tolerance in non-Diabetic Subjects

Alexander Vonbank^{1,2,3}, Christoph H. Saely^{1,2,3}, Philipp Rein^{1,2,3}, Stefan Aczel^{1,2}, Joachim Blocher¹, Stefan Beer^{1,2,3}, Veronika Kiene¹, Thomas Bochdansky⁴, Heinz Drexel^{1,2,3}
(1) Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch (2) Academic Teaching Hospital Feldkirch (3) Private University in the Principality of Liechtenstein, Triesen, Liechtenstein (4) Hospital Rankweil, Department of Physical Medicine

P68 Insulin Resistance is Associated with Metabolic Syndrome But Not With Angiographically Determined Coronary Artery Disease

Alexander Vonbank^{1,2,3}, Christoph H. Saely^{1,2,3}, Philipp Rein^{1,2,3}, Stefan Beer^{1,2,3}, Magdalena Woess¹, Johannes Breuss¹, Barbara Gaensbacher¹, Heinz Drexel^{1,2,3}
(1) Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch (2) Academic Teaching Hospital Feldkirch (3) Private University in the Principality of Liechtenstein, Triesen, Liechtenstein

P69 Type 2 Diabetes and the Coronary Angiographic State are Mutually Independent Predictors of Future Vascular Events Among Angiographed Coronary Patients

Christoph H. Saely^{1,2,3}, Tobias Gansch¹, Susanne Greber¹, Philipp Rein^{1,2,3}, Alexander Vonbank^{1,2,3}, Stefan Beer^{1,2,3}, Fabian Schmid^{1,2}, Thomas Marte^{1,2}, Heinz Drexel^{1,2,3}
(1) Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch (2) Academic Teaching Hospital Feldkirch (3) Private University in the Principality of Liechtenstein, Triesen, Liechtenstein

P70 Association Between Bone Mineral Density And Coronary Atherosclerosis in Patients With Type 2 Diabetes

Stefan Beer^{1,2,3}, Christoph H. Saely^{1,2,3}, Philipp Rein^{1,2,3}, Alexander Vonbank^{1,2,3}, Johannes Breuss¹, Heinz Drexel^{1,2,3}
(1) Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch (2) Academic Teaching Hospital Feldkirch (3) Private University in the Principality of Liechtenstein, Triesen, Liechtenstein

P71 What are the relations between the metabolic syndrome, endothelial function and intima-media thickness in asymptomatic 30-45 years old individuals?

O. Polikina, MD, V.Vikentyev, MD, PhD
Department of the Internal Medicine and Occupational Health, Moscow State University of Medicine and Dentistry – Moscow – Russia

P72 Insulin and C-peptide relationships in insulin resistant patients with obesity-associated hypertension

Goptsi E.

P73 Prevalence of the metabolic syndrome components and their combinations in men and women with acute coronary syndrome (Moscow-based study)

V.Vikentyev, MD, PhD, O. Polikina, MD

Department of the Internal Medicine and Occupational Health, Moscow State University of Medicine and Dentistry – Moscow – Russia

P74 TGF- β 1 Gene Polymorphisms and Susceptibility to nephropathy in Tunisian Type 1 Diabetic population

Benmansour Jihen, Stayoussef Mouna, Almawi Wassim, Mahjoub Touhami

Unité de recherche Biologie et Génétique des Cancers et des Maladies Hématologiques et Auto-immunes. Faculté de Pharmacie – Monastir.

P75 Risk factors of non-alcoholic steatohepatitis in Tunisian type 2 diabetic subjects

M.Hassine¹, F.Ben Mami¹, K.Bouzi², A.Bahlous², S.Dakhli¹, A.Trimeche¹, J.Abdelmoula², O.Saadi³, A.Achour¹

(1) Department of Diabetology and Clinical Nutrition – National Institute of Nutrition – Tunis Tunisia (2) Biochemistry Department – Charles Nicolle Hospital; Tunis-Tunisia (3) Department of Radiology – Salah Azaiz Institute; Tunis- Tunisia

P76 Cardiovascular factors in Tunisian type 2 diabetic subjects with metabolic syndrome

F.Ben Mami¹, M.Hassine¹, K.Bouzi², A.Bahlous², S.Dakhli¹, A.Trimeche¹, J.Abdelmoula², A.Achour¹

(1) Department of Diabetology and Clinical Nutrition – National Institute of Nutrition – Tunis Tunisia (2) Biochemistry Department – Charles Nicolle Hospital; Tunis-Tunisia

P77 Relationship between inflammatory markers and carotid intima-media thickness in obese patients

Olivia Georgescu¹, Anca Sirbu^{1,2}, Carmen Barbu^{1,2}, Suzana Florea¹, Simona Fica^{1,2}

(1) Elias University Emergency Hospital – Bucharest, Romania (2) University of Medicine and Pharmacy Carol Davila – Bucharest, Romania

P78 Possible Effect of Maternal Thyroid Status and Mild Iodine Deficiency on Birth Size and Cord Blood IRI, GH and IGF – I Levels

*N.Beridze, M.Japaridze, K.Sakhvadze, M.Iashvili, *M.Dundua.*

D.Koridze Maternity Home; *Georgian Diabetes Center; Tbilisi, Georgia

P79 POLYCYSTIC OVARY SYNDROME ACCOMPANIED BY HYPERTENSION AND OBESITY: A PREMATURE ASSOCIATION?

Kovalyova O., Popova S.

Kharkiv National Medical University, Ukraine

P80 Investigation of total antioxidant status in hyperhomocysteinemia experimentally induced in rats

Filip C.¹, Albu E.², Zamosteanu N.¹, Jerca L.¹, Gheorghita N¹

University of Medicine and Pharmacy “Gr.T.Popa” Iași, Romania

(1) Faculty of Medicine, Department of Biochemistry (2) Faculty of Medicine, Department of Pharmacology

P81 Association between obesity, high blood pressure and diabetes mellitus in Russia.

S.Shalnova MD, PhD, A. Deev PhD, N.Karamnova MD

State Research Center for Preventive Medicine – Moscow – Russia

P82 Relations between resistin, leptin, myeloperoxidase and vasomotor responses in insulin resistant patients

P.Tretjakovs PhD^{1,2}, A. Jurka PhD^{1,2}, I. Bormane¹, D. Reihmane¹, I. Mikelsons¹, L. Balode², J.I. Aivars PhD¹, V. Pirags MD^{1,2}

(1) University of Latvia, Riga, Latvia (2) Pauls Stradins Clinical University Hospital, Riga, Latvia

P83 Insulin Resistance Level Relates Inversely to FASN Expression in Human Adipose Tissue

MD. Mayas PhD^{a,b}, FJ. Ortega MD^{b,c}, M. Macías-González PhD^b, R. Bernal PhD^{a,b}, R. Gómez-Huelgas PhD^d, JM. Fernández-Real PhD^{b,c}, FJ. Tinahones PhD^{a,b}

(a) Servicio de Endocrinología y Nutrición, Hospital Virgen de Victoria de Málaga – Spain, (b) CIBEROBN (CB06/03/010), (c) Servicio de Diabetes, Endocrinología y Nutrición, Instituto de Investigación Biomédica de Girona – Spain, (d) Servicio de Medicina Interna, Hospital Carlos Haya de Málaga – Spain.

List of poster abstracts

P84 Associations between lactase persistence and the metabolic syndrome: a cross-sectional study in the Canary Island

Ricardo Almona, Eva E. Alvarez-Leonb, Peter Engfelda, Lluís Serra Majemb, Torbjörn k. Nilssonc

(a) Family Medicine Research Centre, School of Health and Medical Sciences, Örebro University, Örebro, Sweden (b) Department of Clinical Sciences, Faculty of Health Sciences, University of Las Palmas de Gran Canaria, and Service of Preventive Medicine. University Hospital Insular of Gran Canaria, Canarian Health Service, Canary islands, Spain (c) Department of Clinical Chemistry, Örebro University, Örebro, Sweden

P85 Protocatechuic acid counteracted oxLDL-induced apoptosis in macrophages by inhibiting p38-dependent p53 activation

C. Giovannini, R. Vari, B. Scazzocchio, M. D'Archivio, C. Santangelo, C. Filesì, R. Masella

Istituto Superiore di Sanità, Rome, Italy.

P86 Sitagliptine induced peritracheal edema : a case-report

Skalli S.¹, Wion N.², Baudrant Magalie¹, Benhamou PY², Halimi S².

(1) Département de pharmacie, Centre Hospitalier Universitaire de Grenoble, Grenoble 38043, France

(2) Service d'endocrinologie et de diabétologie, Pôle Digidune Centre Hospitalier Universitaire de Grenoble, Grenoble 38043, France

P88 Microalbuminuria as an early marker for cardiovascular disease in obese subjects

Benahmed.I., Ounaissa.K, Hassine.M, C Kacem A., JamoussiH, Amrouche, Sellami.H., Blouza Chabchoub.S

Departement of diabetology and nutrition of PR Blouza ,National institute of nutrition in tunisia .TUNIS

P89 What about High sensitivity C - reactive protein in early diagnosed type 2 diabetic patients?

K.Bouzid¹, F.Ben Mam², M.Hassine², N.Ghrairi¹, R.Zrifi³, S.Hammami¹, A.Bahlous¹, A.Achour², J.Abdelmoula¹.

(1) Biochemistry Department- Charles Nicolle Hospital;Tunis-Tunisia. (2) Department of Diabetology and Clinical Nutrition-National Institute of Nutrition;Tunis-Tunisia (3) Department of Medicine and Sports Sciences;Tunis-Tunisia

P90 Microalbuminuria and brain natriuretic peptide: important markers in type 2 diabetic patients

K.Bouzid¹, M.Hassine², A.Bahlous¹, N.Ghrairi¹, L.Zerelli¹, F.Ben Mam², A.Achour², J.Abdelmoula¹

(1) Biochemistry Department- Charles Nicolle Hospital;Tunis-Tunisia.

(2) Department of Diabetology and Clinical Nutrition-National Institute of Nutrition;Tunis-Tunisia

P91 Diabetes Mellitus presenting as Generalized Chorea - case report

C Matos, F Mota*, ML Pereira*, A Salgado**, J Pinho**, A Frias*, J Fontes***

Endocrinology* and Neurology** Departments, Hospital of St. Marcos, Braga, Portugal

P92 Obesity, Diabetes and Pregnancy – retrospective analysis

C Matos, F Mota, ML Pereira, A Fernandes, A Frias

Endocrinology Department, Hospital of St. Marcos, Braga, Portugal

Information to the faculty and poster authors

YOU ARE A CHAIRMAN

We thank you for proceeding to the CONFERENCE ROOM (ECC D Room) at least 15 minutes prior to the beginning of the session you are chairing.

Speakers have to comply with the speaking time which has been allotted to them.

We thank you in advance for seeing to this parameter.

YOU ARE A SPEAKER

We thank you for proceeding to the PREVIEW ROOM at least 30 minutes prior to the beginning of the session in which you will give a lecture.

Thank you for conforming to the instructions given by the chairpersons of your session.

PREVIEWING YOUR ORAL PRESENTATION

In order to insure the easy running of the scientific sessions, we recommend each speaker to run a few checks on his oral presentation (PowerPoint) or make some technical trials enough time in advance in the PREVIEW ROOM.

A computer expert will welcome you in the PREVIEW ROOM according to the following schedule:

Wednesday May 20th 4.00 p.m. – 6.00 p.m. **Friday May 22nd** 8.00 a.m. – 6.00 p.m.

Thursday May 21st 8.00 a.m. – 7.00 p.m. **Saturday May 23rd** 8.00 a.m. – 5.00 p.m.

(closing between 12.30 p.m. and 01.30 p.m. for lunch)

YOU ARE A POSTER AUTHOR

Posters will be displayed for the whole length of the congress in the Foyer 3 area close to the congress welcome desk area.

Fixing materials will be available at the congress welcome desk.

Poster authors are kindly requested to comply with the following schedule for mounting and removing their posters:

MOUNTING as from 8.00 a.m. on Thursday May 21st

REMOVAL as from 11.00 a.m. on Sunday May 24th

A poster session will take place on Sunday May 24th, 2009 from 9.00 a.m. to 11.00 a.m.

We thank you for standing close to your poster during coffee breaks in order to discuss your work with delegates. Here is the schedule of the different coffee breaks :

Thursday May 21st 10.30 a.m. – 11.00 a.m. and 4.00 p.m. – 4.30 p.m.

Friday May 22nd 10.30 a.m. – 11.00 a.m. and 3.30 p.m. – 4.00 p.m.

Saturday May 23rd 10.30 a.m. – 11.00 a.m.

ABSTRACT CODIFICATION (ORAL AND POSTER COMMUNICATIONS)

Abstracts related to the oral communications begin either with « AL » or with « LL »

“AL” stands for Academic Lecture (i.e. a lecture given within an Academic Session) and “LL” stands for Laboratory Lecture (i.e. a lecture given within a Laboratory Symposium i.e. a Sponsored Symposium)

The last two digits correspond to the abstract number.

Abstracts related to the poster communications begin with a « P » + abstract number.

General information

DATES AND CONGRESS VENUE

The congress will take place in Berlin (Germany) from Wednesday May 20th through Sunday May 24th 2009.

Estrel Convention Center

Sonnenallee 225 - 12057 Berlin (Germany)

Phone: +49 (0)30 / 6831 - 22522 - Fax: +49 (0)30 / 6831 - 2345

Web site: www.estrel.com

SCIENTIFIC COMMITTEE

Chair: Pr Jean-Charles FRUCHART

President of the International Atherosclerosis Society

Phone: +33 (0)3 20 87 73 56 - Fax: +33 (0)3 20 87 73 60

Members: Mrs Jamila FRUCHART-NAJIB, Pr Patrick DURIEZ, Pr Bart STAELS

ORGANIZING SECRETARIAT

PLB Organisation / MSDA 2009

Hôtel de Créquy - 15 rue de Pontoise - 78100 Saint-Germain-en-Laye (France)

Phone: +33 (0)1 39 04 24 24 - Fax: +33 (0)1 39 04 07 41

Email: msda2009@agence-plb.com

Managing Director: Mr Pascal LE BORGNE

Congress manager: Mrs Lily-Claude LEVASSEUR

OFFICIAL LANGUAGE

The official language of the congress will be English.

Simultaneous translation from English into French will be provided.

REGISTRATION

REGISTRATION FEES			
DEADLINES STATUS	Before 31/12/2008	From 01/01/2009 to 31/03/2009	From 01/04/2009 and on site registration
PARTICIPANT	500 €	540 €	600 €
ABSTRACT AUTHOR	239 €	239 €	239 €
STUDENT*	239 €	270 €	300 €

*Please enclose the official statement or copy of license (valid ID required)

The registration fee includes:

- Attendance to all scientific sessions and entrance to the exhibit and poster areas
- Final program and abstract book
- Attendance certificate, badge and congress bag
- Coffee breaks (21/05, 22/05, 23/05)

MSDA 2009 ONLINE SERVICES

www.msdacongress.com (Registration and abstract forms)

Please refer to the website for any further information you may require concerning your participation in the congress

IMPORTANT DATES

Abstract submission deadline:

April 1st 2009

Pre-registration deadline:

March 27th 2009

OFFICIAL CARRIER



Identifier code: **05062AF**

Validity from 15/05/2009 to 29/05/2009

Discount are applied to a wide range of airfares, in all classes of travel (Espace Première [First], Espace Affaires [Business] and Tempo [Coach] on all Air France flights worldwide.

To access the preferential fares granted for this event, use this link:

www.airfrance-globalmeetings.com

or the website of the event: www.msdacongress.com

This present document of the event serves to justify the application of the preferential airfare. Keep it with you as you may be asked for it at any point of your journey.

To locate your nearest Air France sales point, consult: www.airfrance.com

Congress from A to Z

ABSTRACT BOOK

This book is available to all registered delegates.

Abstracts have been coded according to the type of lecture (see the "Lectures" section).

- **AL** (Academic Lectures – Academic Session)
- **LL** (Laboratory Lectures – Sponsored Symposia and Lunch Debates)

BADGES

All participants are kindly requested to wear badge at all times throughout the congress and during social events.

BLUE for DELEGATES

GREEN for EXHIBITORS and PRESS

RED for FACULTY (speakers and chairpersons)

YELLOW for ORGANIZATION

CERTIFICATE OF ATTENDANCE

Each registered participant will find the corresponding certificate of attendance in the congress kit at the congress welcome desk.

COFFEE BREAKS – ECC C ROOM

They will be served to all registered participants during the following time schedule:

Thursday May 21st from 10.30 a.m. to 11.00 a.m. and from 04.00 p.m. to 04.30 p.m.

Friday May 22nd from 10.30 a.m. to 11.00 a.m. and from 03.30 p.m. to 04.00 p.m.

Saturday May 23rd from 10.30 a.m. to 11.00 a.m.

EXHIBITION – ECC C ROOM

Opening hours of the exhibition:

Thursday May 21st 8.00 a.m. – 6.00 p.m.

Friday May 22nd 8.00 a.m. – 6.00 p.m.

Saturday May 23rd 8.00 a.m. – 6.00 p.m.

INSURANCE

The organizers cannot be held liable for medical, travel or personal claims. Participants are strongly advised to seek personal insurance coverage.

LECTURES

Please note that lectures have been coded as follows:

- **AL** (Academic Lectures – Academic symposia)
- **LL** (Laboratory Lectures – Supported symposia and lunch debates)

MESSAGES

Should you wish to leave a message to another participant, please report to the congress welcome desk. Please regularly consult the message board located near the congress welcome desk.

NO SMOKING

Please remember that smoking is prohibited within the Salle des Ministres and in the poster and exhibition areas.

OPENING CEREMONY

All registered delegates are invited to attend the Congress Opening Ceremony to be held on Thursday, May 21st, 2009 from 8.45 a.m. to 9.00 a.m.

POSTER DISPLAY – FOYER 3 AREA

Posters are displayed for the whole duration of the congress. They must be set up in the poster display. Please set up your poster according to the poster number you have been given (refer to the list in the poster display area). Hanging fixtures are available in this area. Authors are requested to mount their poster as of 8.00 am on Thursday, May 21st, 2009.

OPENING HOURS OF THE POSTER EXHIBITION

Thursday May 21st	8.30 a.m. – 5.30 p.m.	Friday May 22nd	8.30 a.m. – 6.00 p.m.
Saturday May 23rd	8.30 a.m. – 5.00 p.m.		

PREVIEW ROOM / ECC D ROOM

In order to insure the easy running of the congress, all speakers must proceed to the Preview room in advance in order to have their oral presentation loaded. A computer technician will be in the Preview room according to the following schedule:

Wednesday May 20th	4.00 p.m. – 6.00 p.m.	Thursday May 21st	8.00 a.m. – 7.00 p.m.
Friday May 22nd	8.00 a.m. – 6.00 p.m.	Saturday May 23rd	8.00 a.m. – 5.00 p.m.

(closing between 12.30 p.m. and 01.30 p.m. – lunch time)

Your Destination. Our home.

Welcome to Berlin – home of Bayer Schering Pharma



Cardiovascular diseases are one of the main global causes of death and unfitness for work.

- **Bayer Schering Pharma** is at the **forefront of cardiovascular care** with marketed and pipeline products, spanning the entire cardiology spectrum, to **prevent and treat both acute and chronic diseases**.
- **Bayer Cardiology** is building on more than a **century of heritage in pioneering novel therapeutic breakthroughs** and expanding into **areas of high unmet medical need in cardiovascular disease**, the world's number one cause of death.

www.bayerscheringpharma.de



Bayer HealthCare
Bayer Schering Pharma



*Open your eyes
to microvascular
complications*



LIPANTHYL[®]
FENOFIBRATE
THERE IS MORE TO IT THAN YOU THINK